RELB Antikörper (AA 400-579)

Produktnummer ABIN7172594

Produktdetails anti-RELB Antikörper

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Bindungsspezifität: AA 400-579

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser RELB Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Kreuzreaktivität: Human, Maus

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Transcription factor RelB protein (400-579AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:500,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu RELB

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Andere Bezeichnung: RELB (RELB Produkte)

Synonyme: shep antikoerper, I-REL antikoerper, IREL antikoerper, REL-B antikoerper, XRelB antikoerper, relb-A antikoerper, GC-rich antikoerper, avian reticuloendotheliosis viral (v-rel) oncogene related B antikoerper, RELB proto-oncogene, NF-kB subunit antikoerper, v-rel avian reticuloendotheliosis viral oncogene homolog B S homeolog antikoerper, Relb antikoerper, RELB antikoerper, relb.S antikoerper

Hintergrund:

Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.

Aliases: I REL antibody, I-Rel antibody, IREL antibody, Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody, relB antibody, RELB_HUMAN antibody, Reticuloendotheliosis viral oncogene homolog B antibody, Transcription factor Rel B antibody, Transcription factor RelB antibody, v rel avian reticuloendotheliosis viral oncogene homolog B antibody, v rel reticuloendotheliosis viral oncogene homolog B antibody

UniProt: Q01201

Pathways: NF-kappaB Signalweg, RTK Signalweg